| |
| |
|
| Insider
Information: |
Deleage Jean |
| Relationship: |
Nolonger Director or 1... |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
2,434 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$5,245 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
2,434 |
|
|
| Total
Value |
$5,245 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Rigel Pharmaceuticals Inc |
RIGL |
Director |
2005-11-02 |
697 |
2005-11-02 |
0 |
Premium* |
|
|
Cutera Inc |
CUTR |
No longer 10% Owner |
2005-02-22 |
1,737 |
2005-02-22 |
0 |
Premium* |
|
|
Cyclacel Pharmaceuticals Inc |
CYCC |
Nolonger Director or 1... |
2006-12-01 |
0 |
2006-12-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
18 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CYCC |
Cyclacel Pharmaceuticals ... |
Nolonger Director or 10% Owner |
– – – |
2006-12-01 |
4 |
S |
$6.33 |
$723,133 |
I/I |
(114,239) |
0 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2005-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
697 |
697 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2005-11-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(327,027) |
0 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2005-07-27 |
4 |
S |
$20.55 |
$920,550 |
I/I |
(44,800) |
11,604 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2005-07-26 |
4 |
S |
$20.26 |
$2,576,617 |
I/I |
(127,197) |
13,194 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2005-07-25 |
4 |
S |
$20.37 |
$130,350 |
I/I |
(6,400) |
17,707 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2005-07-21 |
4 |
S |
$20.75 |
$12,160 |
I/I |
(586) |
17,934 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2005-07-20 |
4 |
S |
$20.75 |
$2,337,212 |
I/I |
(112,634) |
17,955 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2005-07-19 |
4 |
S |
$20.76 |
$735,264 |
I/I |
(35,409) |
21,952 |
|
- |
|
| CUTR |
Cutera Inc |
No longer 10% Owner |
– – – |
2005-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,737 |
1,737 |
|
- |
|
| CUTR |
Cutera Inc |
No longer 10% Owner |
– – – |
2005-02-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,000,000) |
0 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2004-11-05 |
4 |
S |
$26.11 |
$3,290,674 |
I/I |
(126,050) |
23,207 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2004-11-05 |
4/A |
S |
$26.11 |
$3,290,674 |
I/I |
(126,050) |
23,208 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2004-10-21 |
4 |
S |
$25.03 |
$4,448,065 |
I/I |
(177,600) |
27,680 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2004-10-19 |
4 |
S |
$26.26 |
$707,704 |
I/I |
(26,950) |
33,981 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2004-10-18 |
4 |
S |
$26.33 |
$510,726 |
I/I |
(19,400) |
34,937 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2004-09-30 |
4 |
S |
$24.79 |
$635,282 |
I/I |
(25,625) |
0 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2004-09-29 |
4 |
OE |
$5.76 |
$1,106,951 |
I/I |
192,179 |
35,625 |
|
- |
|
18 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
